Elan Pharmaceuticals, Inc.

Other

Buck Institute for Research on Aging

University of California

Eli Lilly and Company

Pharmacia & Upjohn Company

Athena Neurosciences, Inc.

Nantneuro, LLC

Pharmacia & Upjohn

Elan Corporation, Plc

Elan Oharmaceuticals, Inc.

The Buck Institute for Age Research

Varghese John

Jay S Tung

Eugene D Thorsett

Lee H Latimer

Jeffrey S Nissen

Jing Wu

Thomas Edward Mabry

Jon Kevin Reel

Warren Jaye Porter

Lawrence Y Fang

James Joseph Droste

Thomas Charles Britton

James E Audia

Roy K Hom

Barbara Jagodzinska

Dale E Bredesen

Michael A Pleiss

Bruce Anthony Dressman

William Leonard Scott

Russell Dean Stucky

Steven Scott Henry

Stephen B Freedman

James A Audia

Andrea Gailunas

Sukanto Sinha

Stacey L McDaniel

John P Anderson

R Jeffrey Neitz

Lisa Claire McConlogue

Guriqbal Basi

Cynthia L Cwi

Michel Maillard

Beverly K Folmer

Gwen Tatsuno

Normand Frigon

Minh Tam Doan

Michael Power

Shuwen Wang

Shumeye Mamo

Patricia R Spilman

James Beck

Shon R Pulley

John Alan Tucker

Mohammad Parvez Alam

John Nicholas Freskos

Ruth Elizabeth TenBrink

Jesus Campagna

James Peter Beck

George W Huffman

Jose Aquino

David Louis Brown

Louis Brogley

John W Mickelson

Celia A Whitesitt

Robert Owen Hughes

Gary D Probst

Russell E Rydel

Ashley C Guinn

Ichiro Nishimura

Clark Norman Eid

Eric T Baldwin

Denis Evseenko

Benjamin J Van Handel

Dale Bredesen

Neerav Shah

Lakshman Samala

Naren Subbiah

Larry Fang

Ruth Tenbrink

Daniel P Getman

Yvette M Fobian

Arthur Glenn Romero

Darren B Dressen

Francine S Grant

Simeon Bowers

Oleksandr V Buzko

Michael S Dappen

Gregory Alan Stephenson

Daniel H Rich

Jian Liu

Brian Alan Sherer

Jennifer Sealy

Lawrence C Fritz

Jon S Jacobs

Richard A Steinhardt

Benjamin Alan Diseroad

Joseph B Moon

Clare Peters-Libeu

John Jacobs

Ying Zi Xu

Kanagasabai Vadivel

Jeffrey Neitz

Tina Bilousova

Ruth T TenBrink

Peter James Heinzelman

Jennifer Sealey

Irina Kramerova

Asa Hatami

Barbara Jagodinska

In various embodiments deformable nano-scale vehicles (DNV) are provided that are useful for the delivery of therapeutic agents. In certain embodiments the DNVs are capable of transdermal delivery and can additionally cross the blood-brain barrier.

Deformable nano-scale vehicles (DNVS) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery

Compositions and methods of use for a compound having a chemical structure of Formula (I) and/or Formula (VII), or a pharmaceutically y acceptable salt or solvate thereof, to increase muscle mass, muscle oxidative capacity, and muscle function and to treat muscular dystrophy, in particular limb girdle muscular dystrophy type 2A/R1/D1 are disclosed.

Compositions and methods for increasing muscle mass and oxidative metabolism

Pharmaceutical compounds, compositions, methods, and uses therefor are presented using selected triazolopyridines and triazolopyrimidines to inhibit or reduce phosphorylation of tau proteins or that act as antagonists of corticotropin-releasing factor. Viewed from another perspective, compounds, compositions, and methods are presented for treating or preventing symptoms of Alzheimer's disease by inhibiting or reducing the phosphorylation of tau proteins.

Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau

In certain embodiments APP-specific BACE inhibitors (ASBIs) are provided as well as uses thereof. In certain embodiments methods of preventing or delaying the onset of a pre-Alzheimer's condition and/or cognitive dysfunction, and/or ameliorating one or more symptoms of a pre-Alzheimer's condition and/or cognitive dysfunction, or preventing or delaying the progression of a pre-Alzheimer's condition or cognitive dysfunction to Alzheimer's disease are provided where the method involves administering to a subject in need thereof an APP specific BACE inhibitor (ASBI) in an amount sufficient to prevent or delay the onset of a pre-Alzheimer's cognitive dysfunction, and/or to ameliorate one or more symptoms of a pre-Alzheimer's cognitive dysfunction, and/or to prevent or delay the progression of a pre-Alzheimer's cognitive dysfunction to Alzheimer's disease. In certain embodiments the ASBI is a flavonoid (e.g. galangin) or flavonoid prodrug (e.g., galangin prodrug).

APP specific bace inhibitors (ASBIs) and uses thereof

In various embodiments, compositions and methods are provided for treatment and/or prevention of amyloidogenic diseases. In certain embodiments, the methods entail administering an effective amount of a tropinol ester to a subject in need thereof for prophylactic or therapeutic effect. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In certain embodiments, methods of reducing the risk, lessening the severity, or delaying the progression or onset of a disease characterized by beta-amyloid deposits in the brain of a mammal are also provided. In certain embodiments, methods of directly or indirectly inhibiting the C-terminal cleavage of APP resulting in the formation of APP-C31 peptide and APPneo (AP-P664) in a mammal are provided.

Tropinol esters and related compounds to promote normal processing of APP

There are provided, inter alia, methods and compounds for activating a proliferative program in competent adult chondrocytes.

Small molecules that enable cartilage rejuvenation

In various embodiments methods are provided for identifying and/or quantifying one or more antigens of interest (biomarkers) on the surface of cell- or tissue-specific exosomes. In an illustrative embodiments the methods comprise: i) incubating a population of exosomes with one or more tissue-specific antibodies that bind an antigen specific to a tissue or cell type of interest that produces exosomes, where the tissue specific antibodies are attached to acceptor bead or magnetic beads so the antibodies bind exosomes displaying the antigen; ii) obtaining a purified population of exosomes bound by the tissue specific antibodies with and/or without photocleavable linker based technology; iii) incubating a test subset of the isolated tissue-specific exosomes with acceptor beads attached to test antibodies that bind an antigen of interest thereby binding exosomes that display the antigen of interest and a control subset with negative control acceptor beads; v) incubating the test subset of isolated exosomes and the control subset of exosomes with a donor-bearing antibody that binds an exosome specific antigen; and vi) detecting a signal produced upon illumination of the control subset and/or the test; and vii) detecting the antigen(s) of interest.

3D-exoquant method for the analysis of surface molecules and quantification of tissue-specific exosomes in biological fluids

Selected compounds, compositions, and methods for inhibiting BACE are presented that have relatively high selectivity towards APP via interaction of the inhibitor with both BACE and APP.

Compositions for APP-selective BACE inhibition and uses therefor

In certain embodiments hydantoin compounds are provided herein that are effective to inhibit BACE activity against APP. Without being bound to a particular theory, it is believed the activity of the hydantoins identified herein appears to be associated with binding to BACE and/or to APP particularly when these moieties form a BACE/APP complex. Accordingly, it is believed the compounds described herein represent a new class of compounds designated herein as APP-Binding-BACE Inhibitors (ABBIs) and provide a new mechanism to modulate APP processing. The hydantoins described herein appear to show improved brain permeability and functional BACE inhibition.

Hydantoins that modulate BACE-mediated app processing

In various embodiments novel allosteric antagonists of the CRFR1 receptor are provided. It discovered that allosteric CRFR1 receptor antagonists are effective to modulate p-Tau levels in Alzheimer's disease (AD) models. In one illustrative embodiment, a compound that is a CRFR1 receptor antagonist is a compound according to the formula  or a pharmaceutically acceptable salt, ester, amide, solvate, or prodrug thereof.

Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-tau and improve cognition

There are provided, inter alia, compounds and methods useful for the treatment of neurological conditions, such as neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.

GP130 modulators

In certain embodiments compounds corresponding in structure to the formula: are provided that are effective to lower p-tau and/or to prevent or reduce elevation of p-tau, particularly in response to stress (e.g., elevated cortisol levels). The compounds are useful in the treatment or prophylaxis of pathologies characterized by abnormal amyloid plaque and or tangle formation and/or deposition.

Substituted [1,2,3]triazolo[4,5-d]pyrimidines that lower stress-induced p-tau

Growing community of inventors

San Francisco, CA, United States of America

Varghese John